RecruitingPhase 1NCT06545331

Study of XB010 in Subjects With Solid Tumors

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor

Exelixis

Enrollment

396 participants

Start Date

Aug 6, 2024

Study Type

INTERVENTIONAL

Conditions

Locally Advanced or Metastatic Solid Tumors NSCLC (Non-small Cell Lung Cancer)Esophageal Squamous Cell Cancer Head and Neck Squamous Cell Cancer

Summary

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called XB010 in people with solid tumors — cancers that form lumps in the body, as opposed to blood cancers — including lung cancer, breast cancer, head and neck cancer, esophageal cancer, and triple-negative breast cancer. **You may be eligible if...** - You are 18 or older with a confirmed advanced, metastatic, or recurrent solid tumor that cannot be surgically removed - Your cancer type is one of: non-small cell lung cancer, hormone receptor-positive breast cancer, head and neck cancer, esophageal squamous cell carcinoma, or triple-negative breast cancer - You are in good physical condition (ECOG 0–1) with adequate organ function **You may NOT be eligible if...** - You have poor organ function (liver, kidneys, blood counts) - You are unable to comply with the study schedule - You have a serious active infection or other uncontrolled condition Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXB010

IV administration of XB010

DRUGPembrolizumab

IV administration of Pembrolizumab

Locations(19)

Exelixis Clinical Site #4

Irvine, California, United States

Exelixis Clinical Site #19

Los Angeles, California, United States

Exelixis Clinical Site #10

Washington D.C., District of Columbia, United States

Exelixis Clinical Site #18

Orlando, Florida, United States

Exelixis Clinical Site #12

Atlanta, Georgia, United States

Exelixis Clinical Site #15

Chicago, Illinois, United States

Exelixis Clinical Site #5

St Louis, Missouri, United States

Exelixis Clinical Site #3

Huntersville, North Carolina, United States

Exelixis Clinical Site #6

Oklahoma City, Oklahoma, United States

Exelixis Clinical Site #9

Nashville, Tennessee, United States

Exelixis Clinical Site #1

Austin, Texas, United States

Exelixis Clinical Site #7

Dallas, Texas, United States

Exelixis Clinical Site #8

Houston, Texas, United States

Exelixis Clinical Site #11

Fairfax, Virginia, United States

Exelixis Clinical Site #2

Fairfax, Virginia, United States

Exelixis Clinical Site #17

Leicester, England, United Kingdom

Exelixis Clinical Site #13

London, England, United Kingdom

Exelixis Clinical Site #16

London, England, United Kingdom

Exelixis Clinical Site #14

Manchester, England, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06545331

Related Trials

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT0630779515 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT0558100441 locations

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT0625387148 locations

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

NCT075282741 location

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT0683556910 locations